ICML 2023 | Treatment approaches, unmet needs, and ongoing research in younger patients with PMBCL

Primary mediastinal B-cell lymphoma (PMBCL) is a rare, distinct subtype of non-Hodgkin lymphoma (NHL). Lisa Roth, MD, Weill Cornell Medicine, New York, NY, discusses PMBCL in children, adolescents and young adults, highlighting the unique biology of the disease, current treatment options available, and unmet needs in younger patients. Adult patients typically receive rituximab-based chemotherapies such as R-CHOP and, more recently, EPOCH-R, but pediatric patients often experience inferior outcomes following typical treatment protocols. Dr Roth highlights the need for new treatments and describes an ongoing Phase III randomized trial evaluating nivolumab in addition to chemotherapy for patients with previously untreated PMBCL. To conclude, Dr Roth elaborates on the unmet needs in younger patients, such as the lack of known biomarkers which could be used to predict disease outcomes. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.